fashion -WSS

fashion

author：fashion 2025-09-30 17:29:53 - browse：97622

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Montana youths win climate lawsuit against state for promoting fossil fuels

leisure time

entertainment

WSS

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Mark Cuban is blaming the wrong people for high drug costs

FDA weighs limits of animal data in assessing artificial wombs

Treatments for cramps don't cut it. Why aren't there better options?

Illinois Supreme Court finds assault weapons ban constitutional

FDA panel to weigh safety of artificial wombs for preterm births

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Montana youths win climate lawsuit against state for promoting fossil fuels

Heart attack and stroke risk calculators need revising

How the messy conversation about Dolly changed bioethics

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Judge sides with young activists in first

The high cost of giving birth even with insurance

Patients, doctors press FTC to beef up hospital merger scrutiny

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How the messy conversation about Dolly changed bioethics

hotspot

Treatments for cramps don't cut it. Why aren't there better options?

Grad students accuse University of California of wage theft

Illumina slashes 2023 revenue projections yet again

House panel takes first step toward fixing drug shortages

Patients, digital health players weigh in on FTC's data privacy plan

Hospitals are dialing back on venture capital investing

leisure time

explore

entertainment

focus